Skip to main content
. 2024 Apr 3;9:78. doi: 10.1038/s41392-024-01780-w

Fig. 4.

Fig. 4

Current approaches to manufacture rAAV. Currently, two main platforms are used for rAAV manufacturing: transfection- and viral infection-based approaches. Plasmid transient transfection of HEK293 cells remains the most widely used method, while stable cell lines, baculovirus (BV) systems, and the HSV type I system offer scalable alternatives for large-scale production. The transfection-free helper virus system TESSA has been developed to produce high-yield rAAVs. Pharmaceutically inducible all-in-one producer cell lines may represent the next generation’s optimal manufacturing platform for rAAV-based drugs. BHK baby hamster kidney. Figure created with Biorender.com